Uniplan Investment Counsel Inc. Decreases Holdings in Petmed Express Inc (PETS)

Uniplan Investment Counsel Inc. reduced its stake in Petmed Express Inc (NASDAQ:PETS) by 3.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 228,072 shares of the company’s stock after selling 8,283 shares during the period. Uniplan Investment Counsel Inc. owned 1.10% of Petmed Express worth $5,304,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Capital Investment Advisory Services LLC acquired a new position in Petmed Express in the fourth quarter valued at approximately $26,000. Quantamental Technologies LLC acquired a new position in Petmed Express in the fourth quarter valued at approximately $71,000. Oregon Public Employees Retirement Fund acquired a new position in Petmed Express in the fourth quarter valued at approximately $183,000. First Hawaiian Bank acquired a new position in Petmed Express in the fourth quarter valued at approximately $193,000. Finally, Gabelli Funds LLC acquired a new position in Petmed Express in the fourth quarter valued at approximately $228,000. Institutional investors own 95.04% of the company’s stock.

A number of equities research analysts have recently weighed in on PETS shares. BidaskClub cut Petmed Express from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. ValuEngine cut Petmed Express from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Craig Hallum cut their price target on Petmed Express from $25.00 to $18.00 and set a “sell” rating on the stock in a report on Wednesday, January 23rd. Finally, TheStreet cut Petmed Express from a “b” rating to a “c+” rating in a report on Thursday, November 29th. Three equities research analysts have rated the stock with a sell rating and two have given a hold rating to the company. Petmed Express currently has a consensus rating of “Sell” and a consensus target price of $28.00.

PETS opened at $21.17 on Friday. The company has a market cap of $437.67 million, a PE ratio of 10.63 and a beta of 0.52. Petmed Express Inc has a twelve month low of $20.25 and a twelve month high of $46.84.

Petmed Express (NASDAQ:PETS) last released its quarterly earnings results on Tuesday, January 22nd. The company reported $0.38 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.48 by ($0.10). The business had revenue of $60.10 million for the quarter, compared to the consensus estimate of $64.22 million. Petmed Express had a net margin of 14.43% and a return on equity of 32.89%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same period last year, the firm posted $0.44 EPS.

The firm also recently declared a quarterly dividend, which was paid on Friday, February 15th. Stockholders of record on Monday, February 4th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, February 1st. This represents a $1.08 dividend on an annualized basis and a dividend yield of 5.10%.

WARNING: This piece of content was originally reported by PressOracle and is the sole property of of PressOracle. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://pressoracle.com/news/2019/03/17/uniplan-investment-counsel-inc-decreases-holdings-in-petmed-express-inc-pets.html.

Petmed Express Profile

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Featured Story: Is it better to buy a fund with a higher or lower NAV?

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Petmed Express Inc (NASDAQ:PETS).

Institutional Ownership by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

Leave a Reply